Optometrists in Hays, KS Accepting Medicare

13 Optometrists found. Showing 1 - 13

Dr. Braiden Joseph Werth, OD Optometrist Medicare: Medicare Enrolled Practice Location: 625 E 8th St, Hays, KS 67601 Phone: 785-625-2922    Fax: 785-625-2941

Jubilee Eye Care, Llc Optometrist Medicare: Medicare Enrolled Practice Location: 2203 Canterbury Dr, Hays, KS 67601 Phone: 785-625-3937

Eyesmile Vision Llc Optometrist Medicare: Medicare Enrolled Practice Location: 1300a Main St, Hays, KS 67601 Phone: 785-621-4242

Kendall L. Krug, Od Pa Optometrist Medicare: Medicare Enrolled Practice Location: 2203 Canterbury Dr, Hays, KS 67601 Phone: 785-625-3937    Fax: 785-625-7490

Dr. Stacey R Jones, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2203 Canterbury Dr, Hays, KS 67601 Phone: 785-625-3937    Fax: 785-625-7490

Dr. Dan F Schmidt, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 625 E 8th St, Hays, KS 67601 Phone: 785-625-2922    Fax: 785-625-2941

Dr. Michael Alan Hattan, OD Optometrist - Corneal and Contact Management Medicare: Accepting Medicare Assignments Practice Location: 1517 E 27th St, Hays, KS 67601 Phone: 785-625-2226    Fax: 785-625-9167

Werth Eye Group Pa Optometrist Medicare: Not Enrolled in Medicare Practice Location: 625 E 8th St, Hays, KS 67601 Phone: 785-625-2922    Fax: 785-625-2941

Dr. Anthony J Taylor, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1517 E 27th St, Hays, KS 67601 Phone: 785-342-2882    Fax: 785-625-9167

Dr. Kendall L Krug, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2203 Canterbury Dr, Hays, KS 67601 Phone: 785-625-3937    Fax: 785-625-7490

Dan F. Schmidt, O.d. P.a. Optometrist Medicare: Medicare Enrolled Practice Location: 625 E 8th St, Hays, KS 67601 Phone: 785-625-2922    Fax: 785-625-2941

Dr. Nicholas Edward Mondero, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 1517 E 27th St, Hays, KS 67601 Phone: 785-625-2226    Fax: 785-625-9167

Michael A Hattan Od Optometrist Medicare: Medicare Enrolled Practice Location: 1517 E 27th St, Hays, KS 67601 Phone: 785-625-2226    Fax: 785-625-9167

News Archive

Cognitive deficits lead to 'loss of self' among cancer patients

For some cancer patients, side effects impacting cognition don't end with the last dose of chemotherapy. According to a new survey, the cognitive impairment experienced by 14 to 45 percent of cancer patients can be long-lasting and severely affect their personal and professional lives.

First step in development of artificial human testicle

After more than 30 years of unsuccessful efforts by numerous investigators, researchers have now found a way to propagate primary human Sertoli cells in the laboratory. Derived from the testis, it has been difficult to maintain Sertoli cells, the "nurse" cells responsible for overseeing sperm production, outside of the human body.

Researchers identify molecular switch that can avoid inflammation

Our immune system is vital to us and can sometimes overreact causing chronic illnesses, such as for instance rheumatism and allergy. Now, researchers from Umeå University and University of Gothenburg have identified a molecular switch - MYSM1 - that can suppress such an overreaction and avoid inflammation.

No rise in COVID-19 cases as Denmark eases lockdown

Outside of Asia, Denmark became the first nation to ease the forced social distancing norms or lockdown. Last week on Thursday, the officials declared that since the removal of the lockdown, there had been no rise in the number of COVID-19 cases. Their easing of the lockdown rules has been gradual, say the officials, and this process began in mid-April. There have been 9,721 reported cases and 484 deaths due to COVID-19 to date. The number of cases has also declined since 7th April.

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.

Read more Medical News

› Verified 3 days ago